Navigation Links
Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture
Date:7/22/2014

(WASHINGTON, July 22, 2014) The American Society of Hematology (ASH) will honor Michael DeBaun, MD, MPH, of Vanderbilt University School of Medicine, and Robert P. Hebbel, MD, of the University of Minnesota Medical School with the 2014 Ernest Beutler Lecture and Prize for their significant research advances in the area of sickle cell disease.

The Ernest Beutler Lecture, named for the late Ernest Beutler, MD, a past president of ASH and physician-scientist for more than 50 years, is a two-part lectureship that recognizes major translational advances related to a single topic. The award honors two individuals, one who has enabled advances in basic science and another for achievements in clinical science or translational research.

Drs. DeBaun and Hebbel will present their lecture, "Sickle Cell Disease: Improved Understanding but Continued Challenges," at 1:30 p.m. on Monday, December 8, at the 56th ASH Annual Meeting and Exposition in San Francisco. During their lecture, Dr. DeBaun will discuss the significance and optimal treatment of silent strokes in students with sickle cell disease, as well as opportunities to combine culturally sensitive patient-oriented research with humanitarian efforts in Nigeria. Dr. Hebbel will describe his initial observations of sickle red cell adhesivity to the vascular endothelium and subsequent investigations that have resulted in ongoing therapeutics development focused on a specific "chokepoint" facet of sickle vascular biology.

Dr. DeBaun, the recipient of the 2014 Ernest Beutler Prize in Clinical Science, is Vice Chair of Clinical Research and the JC Peterson Endowed Chair in the Department of Pediatrics at Vanderbilt University. He is the founder and director of Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, a medical home model in a community health center for individuals with sickle cell disease care across their life span. After earning a medical degree and master's degree in health services research from Stanford University, he then completed a residency in Pediatrics and a fellowship in Pediatric Hematology-Oncology at St. Louis Children's Hospital and Washington University School of Medicine. He went on to earn a Master of Public Health degree from The Johns Hopkins University Bloomberg School of Public Health and completed a cancer epidemiology fellowship at the National Cancer Institute. Upon completion of his training, he returned to Washington University from 1996 to 2010 and was later recruited to Vanderbilt to create the new sickle cell center.

Dr. DeBaun is an acknowledged international leader in applications of clinical science to the care of individuals with sickle cell disease. His sickle cell disease research is focused on two areas, elucidating the epidemiology, etiology, and optimal therapy for cerebrovascular injury and asthma (obstructive lung disease). In Nigeria and Ghana, he is presently leading an effort to improve the care of children and adults with sickle cell disease and mentoring the next generation of African physicians with a focus on sickle cell disease.

In addition to his critical contributions to understanding the importance and treatment of silent strokes and asthma in sickle cell disease, Dr. DeBaun has become a visible leader among his colleagues through service in professional societies. He has served many different roles for ASH, including his current role as Chair of ASH's Committee on Promoting Diversity and has also served as a faculty member and past director of ASH's Clinical Research Training Institute. Dr. DeBaun is an elected member of the American Society for Clinical Investigation, the Association of American Physicians, the Institute of Medicine of the National Academy of Sciences, and the American Association for the Advancement of Science.

Dr. Hebbel, the recipient of the 2014 Ernest Beutler Prize for Basic Science, is Regents Professor and Clark Professor of Medicine at the University of Minnesota Medical School, where he is the former Director of UM's Vascular Biology Center. He earned his medical degree from the University of Minnesota in 1973 and completed his internship and residency at the University of Washington. Dr. Hebbel returned to the University of Minnesota in 1976 to complete a fellowship in Hematology/Oncology and has remained there ever since.

Through his formative research accomplishments, Dr. Hebbel is credited with redefining the study of sickle cell disease, broadening our understanding from a narrow look at the biophysics of hemoglobin to include an appreciation of vascular endothelial pathobiology. His observation that sickled red blood cells are abnormally adherent to endothelial cells, first reported at the Plenary Scientific Session at the 1978 ASH Annual Meeting and Exposition and later published in the Journal of Clinical Investigation in 1980, led to numerous discoveries that eventually led to an understanding of sickle cell disease as a unique vascular disorder. This evolution of thought has not been limited to a single research approach but has been enabled by the use of molecular, cellular, animal, and clinical tools. Through his abundant basic scientific contributions, Dr. Hebbel has engendered multiple distinct areas of sickle cell research and numerous opportunities for new research careers.

The importance of Dr. Hebbel's work is evidenced through the publication of his research in more than 200 book chapters, reviews, editorials, and peer-reviewed research articles. He is a member of ASH as well as the Central Society for Clinical Research, American Federation for Medical Research, American Society for Clinical Investigation, and the American Association of Physicians.

"The work of Drs. DeBaun and Hebbel has allowed for a vastly improved understanding of sickle cell disease and exemplifies translational research at its very best," said ASH President Linda J. Burns, MD, of the University of Minnesota. "Their research has allowed for the translation of basic laboratory insights to the patient bedside and has resulted in better care for of millions of patients with sickle cell disease around the world."


'/>"/>

Contact: Amanda Szabo
aszabo@hematology.org
202-552-4914
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. Dr. Arthur Slutsky, vice-president of research at St. Michaels, receives lifetime award
2. The Tennessee Car Accident Lawyers at Michael D. Ponce & Associates Alert Public of CDC Survey Revealing Majority of High School Seniors Admitting to Texting Behind Wheel
3. UGR and Michael J. Fox Foundation take a step forward in the study of Parkinsons disease
4. St. Michaels Dr. Sean B. Rourke receives federal funds for iHIV/AIDS research
5. Dr. Michael Reiss is Helping to Reduce Neck and Back Pain in Las Vegas and is Now Welcoming New Patients
6. Dr. Michael Reiss of Southern Nevada Chiropractic Helps Car Accident Patients with Neck or Back Pain by Providing Computerized Spinal Exam and a Copy of His Book
7. Top New Jersey Cosmetic Surgeon Dr. Michael Macri Introduces First and Only Liposuction Center to the New Jersey & New York area
8. NewsWatch features Hyatt Hotel and The Michael Mondavi Family's "Canvas Art of Wine" iPad App on AppWatch
9. Researchers at St. Michaels Hospital test tool for screening cancer patients for malnutrition
10. Advanced Male Medical Center Proud to Announce Addition of Dr. Michael King, MD
11. Michael S. McKee, M.D. Joins North American Spine at San Antonio, Texas Location
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and parties ... healthy, staying active, and taking medication and doing daily foot health checks (a must ... trips, parties and family gatherings can take their toll on our feet during the ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has announced the ... providing occupational safety and health training to public sector employees. , “The primary ...
(Date:12/5/2016)... ... 2016 , ... Edward Buckingham MD , and the ... the newest Sciton laser in January 2017. The Halo is the first and ... wavelengths for exceptional results. Outperforming more traditional lasers, the innovative Halo automatically customizes ...
(Date:12/5/2016)... Petersburg, Fla. (PRWEB) , ... December 05, 2016 , ... ... concussions have on the growing brains of young athletes. Over the course of three ... the head through unique mouth guards. The mouth guards, equipped with special sensors, will ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... company will provide alerting technology to Central Illinois Health Information Exchange (CIHIE) ... in federal funds as the sole sub-recipient participating with the Illinois Health ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... LAKE OSWEGO, Ore. , Dec. 5, 2016 /PRNewswire/ ... in the BioInsight clinical study. The study evaluates the ... 2 insertion procedure in an office setting. ... ProMRI ® technology that is placed underneath a ... atrial fibrillation and syncope (fainting). Atrial fibrillation is a ...
(Date:12/5/2016)... and Gateway Health proudly announce a dynamic collaboration that will ... members with specific high risk needs. In an ... of consumers, Wellbridge combines technology and population expertise with a ... daily behaviors and lifestyle. ... , , "Dealing ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, ... Sankyo) today announced preliminary safety and efficacy data ... investigational oral selective MDM2 inhibitor, suggesting that DS-3032 ... including relapsed/refractory acute myeloid leukemia (AML) and high-risk ... escalation part of the phase 1 study of DS-3032 ...
Breaking Medicine Technology: